Moderna Q4 Earnings Preview: COVID-19 Vaccine Sales, Bird Flu Vaccine Candidates On Watch
Moderna is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to expect in ...
Moderna Stock Falls on Earnings Report. The Results Reaffirm a Grim Picture for Vaccine Maker.
The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...
Moderna outlines $1.5B-$2.5B 2025 revenue target with focus on 10 product approvals
Q4 2024 Management View Moderna CEO Stéphane Bancel highlighted 2024 as a year of significant progress, with revenues reaching $3.2 billion. The company reduced operating expenses by $2.6 billion and ...
Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.
Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Yahoo Finance1 个月
Moderna target nearly halved by Morgan Stanley on weak guidance
Investing.com -- Morgan Stanley slashed its price target on Moderna Inc (BMV ... ongoing competitive pressures in the vaccine market. The firm noted Moderna's reduced 2024 sales forecast of ...
Three Years After Experimental Vaccine, These Patients Are Still Cancer-Free
An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...
HealthDay on MSN15 天
Moderna Receives $590M From HHS to Develop Bird Flu Vaccine
The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.
Yahoo Finance1 个月
Moderna target nearly halved by Morgan Stanley on weak guidance
Investing.com -- Morgan Stanley slashed its price target on Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) to $38 from $70 given the lowered revenue guidance and ongoing competitive pressures in the vaccine ...
Benzinga.com16 天
Moderna Stock Is Sliding Wednesday: Here's Why
Goldman Sachs analyst Salveen Richter downgrades Moderna from Buy to ... success for the company’s EBV vaccine from 85% to 70%. The firm’s 12-month price target is based on a 100% discounted ...
U.S. News & World Report24 天
Moderna Receives $590M From HHS to Develop Bird Flu Vaccine
Moderna’s vaccine is designed to target H5 and H7 avian influenza viruses. The company plans to move into phase 3 clinical trials to test the vaccine in a larger group of people after receiving ...
Moderna (NASDAQ:MRNA) Price Target Cut to $50.00 by Analysts at Evercore ISI
Moderna (NASDAQ:MRNA – Free Report) had its price objective decreased by Evercore ISI from $60.00 to $50.00 in a research report report published on Monday,Benzinga reports. Evercore ISI currently has ...
Yahoo Finance29 天
Moderna price target drops, fintech Outperform, FDA hits tobacco
Moderna's (MRNA) price target slashed to $38 from $70 by Morgan ... Analysts cite lowered 2025 revenue outlook and vaccine market competition. Fintech leaders SoFi (SOFI) and Affirm (AFRM) have ...